Matthew S. Davids, MD | Authors

Articles

A Phase II Study of Ibrutinib Plus FCR as Frontline Therapy in Younger CLL Patients

February 07, 2018

Matthew S. Davids, MD, Associate Director, Dana-Farber Cancer Institute Center for Chronic Lymphocytic Leukemia, discusses a multicenter study of ibrutinib (Imbruvica) plus FCR as a frontline therapy for younger patients with chronic lymphocytic leukemia (CLL).

Using Checkpoint Blockade Inhibitors in Relapsed Hematologic Malignancies After Stem Cell Transplant

December 10, 2017

Matthew S. Davids, MD, Associate Director, Dana-Farber Cancer Institute Center for Chronic Lymphocytic Leukemia, discusses a study that explored optimizing checkpoint blockade as a treatment for relapsed hematologic malignancies after allogenic hematopoietic cell transplantation during the 2017 ASH Annual Meeting.